RC
AGN

RBF Capital’s Allergan plc AGN Stock Holding History

RBF Capital’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-10,000
Closed -$1.77M – 421
2020
Q1 		$1.77M Hold
10,000
– – 0.23% 93
2019
Q4 		$1.91M Hold
10,000
– – 0.18% 114
2019
Q3 		$1.68M Sell
10,000
-2,500
-20% -$407K 0.19% 106
2019
Q2 		$2.09M Buy
+12,500
New +$1.73M 0.21% 96
2018
Q4 		– Sell
-13,300
Closed -$2.53M – 461
2018
Q3 		$2.53M Hold
13,300
– – 0.27% 80
2018
Q2 		$2.22M Sell
13,300
-700
-5% -$112K 0.26% 82
2018
Q1 		$2.36M Buy
+14,000
New +$2.35M 0.28% 80
2017
Q4 		– Sell
-5,000
Closed -$1.02M – 396
2017
Q3 		$1.02M Sell
5,000
-4,000
-44% -$930K 0.13% 134
2017
Q2 		$2.19M Buy
9,000
+2,000
+29% +$470K 0.29% 73
2017
Q1 		$1.67M Buy
+7,000
New +$1.63M 0.23% 90

Other funds holding AGN

AJ
Ashburton (Jersey) St Helier, Jersey $227M AUM
C
Cerebellum San Francisco, California $21.5M AUM
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return
JJ
JDC-JSC New York $20.8M AUM 30.94% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
OPS
Orion Portfolio Solutions Omaha, Nebraska $10.2B AUM 6.73% 1-Year Est. Return

RBF Capital's AGN Position: Q2 2020 in Review

RBF Capital sold out of Allergan plc (AGN) in Q2 2020, closing a stake of 10,000 shares — an estimated $1.77M sold.

RBF Capital first reported a position in AGN in Q1 2017 and held it in 10 quarters. The position peaked at $2.53M in Q3 2018. 7 funds tracked by Wall St. Rank hold AGN as of Q2 2020.

  • RBF Capital reported no remaining Allergan plc position as of Q2 2020 after selling out during the quarter.
  • RBF Capital sold 10,000 Allergan plc shares in Q2 2020, an estimated $1.77M.
  • RBF Capital first reported a position in Allergan plc in Q1 2017 and held it in 10 quarters.
  • RBF Capital's Allergan plc position peaked at $2.53M in Q3 2018.
  • 7 funds tracked by Wall St. Rank held Allergan plc as of Q2 2020.

Based on RBF Capital's 13F filing for Q2 2020, filed 14 Aug 2020.